Charles Zhu's Stock Ratings

Guggenheim Analyst

Charles Zhu is an analyst at Guggenheim. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 06/14/2024

Overall Average Return

12.3%

Smart Score

61.5%

Overall Average Return Percentile

66th

Number of Ratings

19
Buy NowGet Alert
05/24/2024TNGXBuy Now
Tango Therapeutics
$9.0255.21%$16 → $14MaintainsBuyGet Alert
11/07/2023MGNXBuy Now
Macrogenics
$4.50166.67% → $12UpgradeNeutral → BuyGet Alert
08/08/2023MRUSBuy Now
Merus
$56.55-15.12%$46 → $48MaintainsBuyGet Alert
07/24/2023NUVLBuy Now
Nuvalent
$77.78-28% → $56Initiates → BuyGet Alert
07/10/2023TARABuy Now
Protara Therapeutics
$2.60746.15% → $22Assumes → BuyGet Alert
06/13/2023COGTBuy Now
Cogent Biosciences
$8.43208.42% → $26ReiteratesBuy → BuyGet Alert
04/17/2023MRUSBuy Now
Merus
$56.55-20.42%$38 → $45MaintainsBuyGet Alert
03/17/2023MGNXBuy Now
Macrogenics
$4.50——DowngradeBuy → NeutralGet Alert
03/15/2023COGTBuy Now
Cogent Biosciences
$8.43208.42% → $26Reiterates → BuyGet Alert
03/08/2023IDYABuy Now
IDEAYA Biosciences
$38.11-16.03% → $32Reiterates → BuyGet Alert
01/03/2023NLTXBuy Now
Neoleukin Therapeutics
———DowngradeBuy → NeutralGet Alert
12/13/2022COGTBuy Now
Cogent Biosciences
$8.43184.7%$22 → $24MaintainsBuyGet Alert
11/29/2022MDNABuy Now
Medicenna Therapeutics
—— → $2Initiates → BuyGet Alert
11/23/2022MGNXBuy Now
Macrogenics
$4.50166.67% → $12UpgradeNeutral → BuyGet Alert
09/13/2022IDYABuy Now
IDEAYA Biosciences
$38.11-16.03%$20 → $32MaintainsBuyGet Alert
08/16/2022PNTBuy Now
POINT Biopharma Global
—— → $20Initiates → BuyGet Alert
07/18/2022MRUSBuy Now
Merus
$56.55-18.66%$44 → $46MaintainsBuyGet Alert
05/05/2022ZYMEBuy Now
Zymeworks
$9.0454.87% → $14UpgradeNeutral → BuyGet Alert
05/04/2022MGNXBuy Now
Macrogenics
$4.50——DowngradeBuy → NeutralGet Alert